Skip to Main Content

Cover Story

March 14, 2011
Volume 89, Number 11
pp. 18 - 19

Spin-Offs: Meet The Structure Specialists

Carmen Drahl

  • Print this article
  • Email the editor

More Science Stories

October 24, 2011

Bryostatins Retain Promise

(October 24, 2011 | Vol. 89 Issue 43 | pp. 10-17)

New results in total synthesis reinvigorate a 40-year-old field of research.

For Cave's Art, An Uncertain Future

(October 24, 2011 | Vol. 89 Issue 43 | pp. 38-40)

Disagreement on conservation course of action complicates a potential reopening.

Cancer Stem Cells

(October 24, 2011 | Vol. 89 Issue 43 | pp. 41-43)

Researchers zero in on the pathways that allow cancer to bounce back after treatment.

What's That Stuff? Blue Jeans

(October 24, 2011 | Vol. 89 Issue 43 | p. 44)

Making the iconic pants requires both color-addition and color-removal chemistry.

Shedding Nanoparticles

(October 24, 2011 | Vol. 89 Issue 43 | p. 5)

Materials Science: Chemists observe metal objects sloughing off ions to form nanoparticles.

Modifying Messenger RNA

(October 24, 2011 | Vol. 89 Issue 43 | p. 7)

Chemical Biology: Methylated bases in mRNA may have roles in gene regulation and obesity.

Lab-On-A-Chip For Planets, Moons

(October 24, 2011 | Vol. 89 Issue 43 | p. 8)

Microfluidics: Automated chip is designed to detect extraterrestrial amino acids.

New Editor For Analytical Chemistry

(October 24, 2011 | Vol. 89 Issue 43 | p. 9)

Publishing: Jonathan Sweedler to take the helm.

Science & Technology Concentrates

(October 24, 2011 | Vol. 89 Issue 43 | p. 37)


October 17, 2011

Improving Shop Safety

(October 17, 2011 | Vol. 89 Issue 42 | pp. 56-57)

Yale updates policies on machine shop use after student death.

Cleaning Acrylics

(October 17, 2011 | Vol. 89 Issue 42 | pp. 58-59)

Conservation scientists seek new ways to keep modern paintings looking their best.

Detecting H2S In Vivo (Member Content)

(October 17, 2011 | Vol. 89 Issue 42 | p. 60)

Studies could lead to sensitive and selective analyses for tiny signaling agent.

Rules For Design

(October 17, 2011 | Vol. 89 Issue 42 | p. 9)

Materials Science: Guidelines predict structures formed by nanoparticles and DNA linkers.

Identifying Modified Cells

(October 17, 2011 | Vol. 89 Issue 42 | p. 11)

Molecular Biology: Technique tags and enriches cells genetically altered by nucleases.

Linker-Free Molecular Wires

(October 17, 2011 | Vol. 89 Issue 42 | p. 12)

Electronics: Metal-carbon bonds increase electrical conductance.

Asymmetry From A Guest

(October 17, 2011 | Vol. 89 Issue 42 | p. 13)

Stereochemistry: Enzymelike pocket that hosts chiral species controls catalyst's enantioselectivity.

Science & Technology Concentrates

(October 17, 2011 | Vol. 89 Issue 42 | pp. 54-56)


Text Size A A

G-protein-coupled receptors are hot drug targets, and plenty of companies want to know what they look like to get an edge on making new drugs. Despite recent advances, getting X-ray crystal structures for GPCRs is still far from easy.

So companies are joining forces with leading academic labs that solve GPCR structures—those of Brian K. Kobilka at Stanford, Raymond C. Stevens at Scripps Research Institute, Christopher G. Tate at the Medical Research Council (MRC) Laboratory of Molecular Biology in Cambridge, England, and with the start-up companies they’ve each cofounded. This trio of firms is licensing their structure-determining technology and partnering with large drugmakers to crack thorny GPCR targets. And two of the start-ups are showing the world the approach can work through drug discovery efforts of their own.

Kobilka cofounded ConfometRx in 2005 with physician-scientist and spouse Tong Sun. The company is developing a suite of techniques to help companies crystallize GPCRs. “We want to translate some of the technology we’re developing in the lab and make it useful to pharma,” Kobilka says.

One such method is T4 lysozyme fusion technology, which Kobilka’s Stanford team used to determine the structure of the 2-adrenergic receptor, only the second GPCR to succumb to crystallography. Researchers can use the T4 lysozyme protein to replace a loop on the inner portion of a GPCR, providing some stabilization of the flexible GPCR, as well as extra contacts for crystals to form, Kobilka explains. ConfometRx has an exclusive license for T4 technology, but “we generally throw everything we can at a problem,” including T4, antibody strategies, and a host of protein preparation techniques, Kobilka says. His academic lab is also exploring nuclear magnetic resonance technology, something he hopes can someday be part of ConfometRx’s offerings.

“We’d like to be a resource,” Kobilka says. And companies like Bristol-Myers Squibb and Lundbeck have taken them up on that offer by establishing collaborations. “At some point we may want to evolve along the lines of drug development or in silico screening, but right now we’re very small, and we’re focused on developing and refining our technology,” he says.

“It’s hard to pick any one thing we do” to ease GPCR crystallization, says Michael A. Hanson, associate director of structural biology at Receptos. One technique they’ve used successfully involves stabilizing a GPCR with a small compound instead of with a protein. This strategy was successful for solving the A2A adenosine receptor structure in company cofounder Stevens’ lab. Receptos also used that tactic to solve the structure of the GPCR sphingosine-1-phosphate receptor subtype 1, a multiple sclerosis drug target, Hanson says.

That structure helped the company prioritize which chemical scaffolds to pursue in its multiple sclerosis drug discovery program. In January the company announced that one of the small molecules from that program, RPC1063, has reached Phase I human clinical 

The molecule was initially derived from a hit discovered in a screen run at the National Institute of Health’s Molecular Libraries Probe Production Center at Scripps. RPC1063’s structure has not yet been disclosed.

In addition to the company’s own drug discovery efforts, Receptos has licensed its GPCR crystal structure determination technology to Ortho-McNeil-Janssen Pharmaceuticals and has announced a partnership with Eli Lilly & Co. to develop small-molecule drug candidates for a GPCR. Hanson declines to disclose the GPCR target or the disease involved in the Lilly deal.

Across the globe from its fellow start-ups, Heptares Therapeutics gets its GPCR X-ray structures with help from thermal stabilization—a targeted mutation technique developed in cofounders Tate and Richard Henderson’s labs at the MRC Laboratory of Molecular Biology. It’s not fully clear how thermal stabilization works, but it keeps the GPCR from falling apart and traps it in a single state, Tate says.

Those stabilized receptors, or StaRs, have helped Heptares reach a major milestone in its GPCR drug discovery partnership with Novartis. “We’ve achieved success with what was a difficult receptor in a new family,” says Fiona H. Marshall, Heptares’ chief scientific officer. Heptares has not disclosed the GPCR target.

Heptares has also uncovered a compound that blocks the A2A receptor, a GPCR that responds to adenosine. The molecule is in preclinical studies for Parkinson’s disease. The company started its drug discovery program before the A2A receptor’s X-ray structure was determined by using a computer model based on the solved structure of a different GPCR to screen a library of molecules called fragments, with lower molecular weights than normal screening collections. Heptares chemists then built out from the fragment to make compact drug candidates, akin to a method called fragment-based drug discovery (C&EN, July 21, 2008, page 15).

The small molecule that emerged from Heptares’ battery of studies has a molecular weight of under 300, which makes it smaller, and therefore better aligned with guidelines for druglike molecules, than other A2A-targeted Parkinson’s drug candidates, Marshall says.

Partnerships with small companies help push GPCR drug discovery forward, says Bristol-Myers Squibb principal scientist Andrew Tebben. “There are very specialized techniques one has to master to be able to crystallize GPCRs,” he says. Several small companies “have that expertise—they know how to handle these proteins,” he says. By combining that know-how with large-company expertise “we hope to achieve more of our goals.”

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2011 American Chemical Society
  • Print this article
  • Email the editor

Services & Tools

ACS Resources

ACS is the leading employment source for recruiting scientific professionals. ACS Careers and C&EN Classifieds provide employers direct access to scientific talent both in print and online. Jobseekers | Employers

» Join ACS

Join more than 161,000 professionals in the chemical sciences world-wide, as a member of the American Chemical Society.
» Join Now!